文献速递肿瘤 PET/CT核素与放射性配体治疗

68Ga PET显像在神经内分泌肿瘤中的应用:系统评价与Meta分析

68Ga PET Imaging in Patients With Neuroendocrine Tumors: A Systematic Review and Meta-analysis.
PubMed 文献 · Clin Nucl Med · 2018-01-01

该系统评价与Meta分析检索MEDLINE、EMBASE和Cochrane数据库,纳入22项比较PET或PET/CT与传统显像的研究。NETs初诊时PET或PET/CT的汇总敏感度为91%(95%CI 85%-94%),汇总特异度为94%(95%CI 86%-98%);分期与再分期时敏感度为78.3%-100%,特异度为83%-100%;45%(95%CI 36%-55%)的病例治疗管理发生改变,多涉及手术规划和肽受体放射性核素治疗的患者选择。作者推荐68Ga PET或PET/CT用于传统检查仍不明确时的初诊、计划根治性手术的局限原发和/或有限转移患者的分期、确定生长抑素受体状态及PRRT适用性,以及隐匿病变检出会改变治疗选择时的分期。

要点

  • 初诊NETs时68Ga PET或PET/CT汇总敏感度91%、汇总特异度94%。
  • 分期与再分期时敏感度78.3%-100%,特异度83%-100%。
  • 45%的病例治疗管理发生改变,多涉及手术规划与PRRT患者选择。

核心结论

  • 作者推荐68Ga PET或PET/CT用于传统检查仍不明确时的NETs初诊。
  • 作者推荐用于计划根治性手术的局限原发和/或有限转移患者的分期。
  • 作者推荐用于确定生长抑素受体状态及肽受体放射性核素治疗适用性。
  • 作者推荐用于隐匿病变检出会改变治疗选择与决策患者的分期。

研究设计与样本

  • 系统评价与Meta分析,检索MEDLINE、EMBASE和Cochrane Database of Systematic Reviews数据库(经OVID)。
  • 纳入比较PET或PET/CT与传统显像在NETs初诊、分期与再分期、疗效评估及常规监测中应用的研究。
  • 采用QUADAS工具评估偏倚风险与适用性担忧,共22项研究符合纳入标准。

主要发现

  • NETs初诊时,PET或PET/CT汇总敏感度为91%(95%CI 85%-94%),汇总特异度为94%(95%CI 86%-98%)。
  • 分期与再分期时,PET或PET/CT检测原发和/或转移灶的敏感度范围为78.3%-100%,特异度范围为83%-100%。
  • 45%(95%CI 36%-55%)的病例治疗管理发生改变,多数改变涉及手术规划和肽受体放射性核素治疗的患者选择。

关键数值与推荐

  • 初诊NETs:68Ga PET或PET/CT汇总敏感度91%(95%CI 85%-94%),汇总特异度94%(95%CI 86%-98%)。
  • 分期与再分期:检测原发和/或转移灶敏感度78.3%-100%,特异度83%-100%。
  • 治疗管理改变比例45%(95%CI 36%-55%)。

临床怎么用

  • 作者推荐68Ga PET或PET/CT用于传统检查仍不明确时的NETs初诊。
  • 作者推荐用于计划根治性手术的局限原发和/或有限转移患者的分期。
  • 作者推荐用于确定生长抑素受体状态及肽受体放射性核素治疗适用性。
  • 作者推荐用于隐匿病变检出会改变治疗选择与决策患者的分期。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The aim of this study was to systematically review the literature to assess the role of Ga PET imaging in neuroendocrine tumors (NETs). MATERIALS AND METHODS: The literature was searched using MEDLINE, EMBASE, and Cochrane Database of Systematic Reviews databases through OVID. Studies comparing PET or PET/CT with conventional imaging in the initial diagnosis, staging and restaging, assessment of treatment response, and routine surveillance of NETs were deemed eligible for inclusion. Risk of bias and applicability concerns were assessed using the Quality Assessment of Diagnostic Accuracy Studies tool. RESULTS: Twenty-two studies met the inclusion criteria. For the initial diagnosis of NETs, PET or PET/CT had a pooled sensitivity of 91% (95% confidence interval [CI], 85%-94%) and a pooled specificity of 94% (95% CI, 86%-98%). In the setting of staging and restaging, the sensitivity of PET or PET/CT for detecting primary and/or metastatic lesions ranged from 78.3% to 100%, whereas specificity ranged from 83% to 100%. Change in management occurred in 45% (95% CI, 36%-55%) of the cases, with majority of the changes involving surgical planning and patient selection for peptide receptor radionuclide therapy. CONCLUSIONS: Ga PET or PET/CT is recommended for initial diagnosis where conventional testing remained equivocal, for staging of patients with localized primary and/or limited metastasis where definitive surgery is planned, to determine somatostatin receptor status and suitability for peptide receptor radionuclide therapy, and for staging of patients where detection of occult disease will alter treatment options and decision making.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Singh S, Poon R, Wong R, et al. 68Ga PET Imaging in Patients With Neuroendocrine Tumors: A Systematic Review and Meta-analysis. Clin Nucl Med. 2018. PMID: 30247209. doi:10.1097/RLU.0000000000002276

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。